Teva mulling $7.5B deal for Barr – Generic Pharmas on the move

Teva also stated it plans to sue Novartis and Momenta for patent infringement. Recently in the news was the announcement to buy Bentley Pharmaceuticals. “Teva USA products are marketed to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies.” A listing of their generic products can be found here at the website. BD

“The world's biggest generics firm may be about to get bigger--a lot bigger. Teva is reportedly in talks to buy Barr Pharmaceuticals for upwards of $5 billion; some reports quote a price as high as $7.5 billion. The latter figure would be a 50 percent premium for Barr, which closed the regular trading day at $46.82 but after hours leapt 19 percent to $55.51 on the news. Reports of the negotiations appeared in two Israel dailies, and a UBS analyst issued a note ticking off reasons a Barr buyout would make sense for Teva: It would give the Israeli company access to the oral contraceptive market, strengthen its European presence and boost efficiencies by "eliminating duplicate infrastructure in the U.S."--which sounds like shutdowns and layoffs to us, but given the fact that no deal's been struck, that's getting the cart before the horse.”